REFERENCES
- Cavazzana A O, Miser J S, Jefferson J, et al. Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol 1987; 127: 507–518
- Mckeon C, Thiele C J, Ross R A, et al. Indistinguishable patterns of protooncogene expression in 2 distinct but closely related tumors—Ewing's sarcoma and neuroepithelioma. Cancer Res 1988; 48: 4307–4311
- van den Berg H, Kroon H M, Slaar A, et al. Incidence of biopsy-proven bone tumors in children: a report based on the dutch pathology registration “PALGA”. J Pediatr Orthop. 2008; 28: 29–35
- Gurney J, Swensen A, Bulterys M. Malignant Bone Tumors, SEER. National Cancer Institute, Bethesda, MD 2006; 99–110, SEER Pediatric Monograph
- Gurney J, Young J, Roffers S. Soft Tissue Sarcomas, SEER. National Cancer Institute, Bethesda, MD 2006; 111–124, SEER, editor. SEER Pediatric Monograph
- Raney R B, Asmar L, Newton W A, et al. Ewing's sarcoma of soft tissues in childhood: A report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. Journal of Clinical Oncology. 1997; 15: 574–582
- Cardous-Ubbink M C, Heinen R C, Langeveld N E, et al. Long-term cause-specific mortality among five-year survivors of childhood cancer. Pediatr Blood Cancer 2004; 42: 563–573
- Maurer H M, Gehan E A, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study II. Cancer. 1993; 71: 1904–1922
- Castex M P, Rubie H, Stevens M CG, et al. Extraosseous localized Ewing tumors: improved outcome with anthracyclines. The French Society of Pediatric Oncology and International Society of Pediatric Oncology. J Clin Oncol 2007; 25: 1176–1182
- Agir H, Brasch H D, Tan S T. Extra-skeletal Ewing's sarcoma of the submandibular gland. J Plast Reconstr Aesthet Surg 2007; 60: 1345–1348
- Nesbit M E, Jr. Gehan EA, Burgert EO, Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8: 1664–1674
- Baldini E H, Demetri G D, Fletcher C D, et al. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg 1999; 230: 79–86
- Burgert E O, Jr, Nesbit M E, Garnsey L A, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990; 8: 1514–1524
- Marina N M, Pappo A S, Parham D M, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol 1999; 17: 180–190
- Kushner B H, Meyers P A, Gerald W L, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995; 13: 2796–2804
- Smith M A, Ungerleider R S, Horowitz M E, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991; 83: 1460–1470
- Grier H E, Krailo M D, Tarbell N J, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348: 694–701
- Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone: a 6-year experience of a European Cooperative Trial. Cancer 1988; 61: 23–32
- Gururangan S, Marina N M, Luo X, et al. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. J Pediatr Hematol Oncol 1998; 20: 55–61